Data / Research funding / Maryland / Rise Therapeutics, LLC
Rise Therapeutics, LLC: 14 NIH awards ($26.6M), fiscal years 2021 to 2026
Rise Therapeutics, LLC in Rockville, MD is funded under 14 NIH awards ($26.6M) in the NIH and NSF award files, read 2026-11-03. NIH fiscal years 2021 to 2025; NSF fiscal years 2022 to 2026.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- UEI
- N36JMJ1DKWH6
- State
- Maryland
Awards
14 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| A Novel Immunologically Enhanced Probiotic for Treating Rheumatoid Arthritis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,922,693 | February 23, 2021 | January 31, 2025 | FANGER, GARY | reporter.nih.gov |
| A Novel Probiotic for the Treatment of Sjogren's Syndrome | NIH | National Institute of Dental & Craniofacial Research | 2021 to 2023 | $2,918,422 | May 12, 2021 | April 30, 2026 | FANGER, GARY | reporter.nih.gov |
| A Novel Microbiome-Based Immune-Modulator that Potentiates Cancer Checkpoint Therapy | NIH | National Cancer Institute | 2021 to 2024 | $2,436,171 | April 1, 2021 | June 30, 2026 | FANGER, GARY | reporter.nih.gov |
| A Novel Immunological-Directed Biotherapy for Treating Rheumatoid Arthritis | NIH | National Institute on Aging | 2023 to 2025 | $2,434,680 | September 4, 2023 | June 30, 2027 | FANGER, GARY | reporter.nih.gov |
| A Novel Immunological-Directed Live Biotherapy Product for Treating Ulcerative Colitis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2024 | $2,277,236 | July 5, 2022 | July 31, 2025 | FANGER, GARY | reporter.nih.gov |
| A Novel Immunological-Directed Synthetic Biology-Based Drug for the Treatment of Multiple Sclerosis | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,090,261 | April 24, 2023 | June 30, 2027 | FURLAN FREGUIA, CHRISTIAN | reporter.nih.gov |
| A Novel Immunologically Directed Probiotic for the Treatment of Type 1 Diabetes | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2023 | $2,083,016 | July 1, 2022 | June 30, 2026 | FURLAN FREGUIA, CHRISTIAN | reporter.nih.gov |
| A Novel Synthetic Biology-Derived Microbiome Therapeutic to Treat Viral-Induced Acute Respiratory Distress Syndrome (ARDS) | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $2,011,001 | January 17, 2023 | December 31, 2025 | FURLAN FREGUIA, CHRISTIAN | reporter.nih.gov |
| R-5280, A Novel Modified Superior Resistant Starch Therapy for Type 1 Diabetes | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2024 | $1,995,869 | September 1, 2023 | August 31, 2025 | FURLAN FREGUIA, CHRISTIAN | reporter.nih.gov |
| A Novel Engineered Probiotic for the Prevention of Clostridium Difficile Infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,887,207 | July 1, 2020 | June 30, 2024 | FANGER, GARY | reporter.nih.gov |
| A Novel Immunological Probiotic for Treating Inflammatory Bowel Disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $1,409,741 | July 1, 2018 | September 30, 2023 | FANGER, GARY | reporter.nih.gov |
| A Novel Synthetically Engineered Oral Immunotherapy for Treating Ulcerative Colitis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2024 to 2025 | $1,377,944 | September 16, 2024 | June 30, 2027 | FANGER, GARY | reporter.nih.gov |
| A Novel Immunological-Directed Probiotic for the Treatment of Sjögren’s Syndrome | NIH | National Institute of Dental & Craniofacial Research | 2025 | $429,158 | August 14, 2025 | August 13, 2026 | FANGER, GARY | reporter.nih.gov |
| A Novel Probiotic Drug Delivery Platform for Oral Administration of Protein-Based Therapies | NIH | National Center for Advancing Translational Sciences | 2022 | $282,514 | July 15, 2022 | July 14, 2024 | FURLAN FREGUIA, CHRISTIAN | reporter.nih.gov |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 4 | $2,914,403 | 0 | $0 |
| 2024 | 7 | $5,683,067 | 0 | $0 |
| 2023 | 9 | $7,511,623 | 0 | $0 |
| 2022 | 8 | $6,251,994 | 0 | $0 |
| 2021 | 5 | $4,194,826 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
Topics of its NIH awards
- Biotechnology
- Microbiome
- Autoimmune Disease
- Complementary and Integrative Health
- Digestive Diseases
- Nutrition
- Immunotherapy
- Prevention
- Clinical Research
- Clinical Trials and Supportive Activities
- Translational Research
- Infectious Diseases
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.